Trial Parameters
Statistical Power (1-β)
96.4%
Risk-Adj. NPV ($M)
$1,450M
P-Value Threshold
< 0.001
Mechanism & Indication
Target: Lipoprotein(a) [siRNA degradation via hepatocyte ASGPR uptake].
Primary Endpoint: MACE reduction (CV death, MI, stroke).
Standard of Care: High-intensity statins + PCSK9i baseline.